Liposomal anthracyclines in metastatic breast cancer: clinical update.
about
Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancerNanotechnologies for biomedical science and translational medicineNewer therapies for the treatment of metastatic breast cancer: a clinical updateDelivery of host cell-directed therapeutics for intracellular pathogen clearanceCharacterization of 9-nitrocamptothecin liposomes: anticancer properties and mechanisms on hepatocellular carcinoma in vitro and in vivo.Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysisFrontiers in cancer nanomedicine: directing mass transport through biological barriersOptimizing the time of Doxil injection to increase the drug retention in transplanted murine mammary tumors.The benefits and challenges associated with the use of drug delivery systems in cancer therapySildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction.Quantitative study of focused ultrasound enhanced doxorubicin delivery to prostate tumor in vivo with MRI guidance.Thioaptamer conjugated liposomes for tumor vasculature targetingClinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacyEnhanced delivery of chemotherapy to tumors using a multicomponent nanochain with radio-frequency-tunable drug releaseWeekly pegylated liposomal doxorubicin and paclitaxel in patients with metastatic breast carcinoma: A phase II study.Anthracycline cardiotoxicity.Applications of nanoparticle drug delivery systems for the reversal of multidrug resistance in cancer.Treatment options for breast cancer resistant to anthracycline and taxaneTargeted drug delivery strategies to treat lung metastasis.Phosphodiesterase 5 inhibitors enhance chemotherapy killing in gastrointestinal/genitourinary cancer cells.Targeting liposomes toward novel pediatric anticancer therapeutics.The use of nanoparticles as a promising therapeutic approach in cancer immunotherapy.Cardio-oncology Part II: the monitoring, prevention, detection and treatment of chemotherapeutic cardiac toxicity.Bridging the Knowledge of Different Worlds to Understand the Big Picture of Cancer Nanomedicines.Recent advances in the preparation and application of multifunctional iron oxide and liposome-based nanosystems for multimodal diagnosis and therapy.Anti-Sp17 monoclonal antibody-doxorubicin conjugates as molecularly targeted chemotherapy for ovarian carcinoma.Nanoscale Biodegradable Organic-Inorganic Hybrids for Efficient Cell Penetration and Drug Delivery.Paclitaxel in tyrosine-derived nanospheres as a potential anti-cancer agent: in vivo evaluation of toxicity and efficacy in comparison with paclitaxel in Cremophor.Molecular mechanisms of pharmaceutical drug binding into calsequestrin.Anandamide preserves cardiac function and geometry in an acute doxorubicin cardiotoxicity rat model.Effect of selective and non-selective cyclooxygenase inhibitors on doxorubicin-induced cardiotoxicity and nephrotoxicity in rats.Translation of combination nanodrugs into nanomedicines: lessons learned and future outlook.Efficacy and toxicity of pegylated liposomal doxorubicin-based chemotherapy in early-stage breast cancer: a multicenter retrospective case-control study.Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer
P2860
Q24657308-691FC45C-9047-4E31-A86D-7A0CACF13B10Q26776376-2AFC0BE5-0F34-439E-A002-33B75A88957BQ26865260-1ACC2247-4D27-4E5D-AFDA-079067774299Q27006858-93C3D08E-BF97-491F-8DD8-EB6511309226Q30475089-8175851F-D2B5-42C3-A9EB-6B1E29B03621Q33404677-6E25B3AE-D810-4EB2-A6D9-02752C316F3EQ33746335-4C2631D2-9295-41B2-AC03-5C7961E526DAQ33831419-7F3AEBB5-82C1-4BB5-BE58-6BC8E5A8E412Q33965271-0C4B2835-C82E-4CD4-B840-311E6B6F338EQ34241307-6A48F49C-010D-4312-9035-BCCF5BB96BD6Q34258440-72AD57D1-6EEF-4EBA-874C-00DC82F53EA6Q35640211-BD857F38-2472-4510-9140-7CEFF4777CB1Q35679856-078A79C2-983D-42B2-9046-A872733564B3Q35981121-C6DDDE5C-2FC2-4E50-BC86-30673D1D11C2Q36216861-0F9C13D4-6AA3-4197-9A29-01281598879BQ36624983-BD2AC94E-77C4-4D28-BB8D-1EE0313976B0Q37002153-C4D9278B-1625-4304-804A-324BD9C2DBBFQ37207961-4E5E5A2E-3CB7-4098-BD46-03C0C8DD842CQ37575499-FD311160-84BA-4590-A3C9-464D5EAA31E3Q37603936-0557C6FB-3CB8-4F01-8D22-0B6E53D2856CQ37684734-7ABDF5CD-9D24-49BE-B480-493AE579824AQ38328927-4FD1C449-5C6E-484D-A922-377FA64F9B5EQ38416816-3AEF23C5-5B9E-46D6-A75D-D4FE6D5E6C10Q38676164-E868D6D3-4278-4AEE-95A5-94E8F16AD3ABQ39030223-A7CFD952-5149-4EC3-89CF-F703D6E02963Q39110485-22F301FF-8863-4309-84EE-BC73C5D1F107Q39255968-A0205A7A-F56B-4E19-B15A-F1D441756BF9Q39430827-C7277471-0896-44AF-8A45-F020C50C0BC1Q42277029-E7D2E37D-58BC-4E97-BDC6-AE9CA463D319Q46171847-451D3C15-35B4-4A4A-8B8D-41140B7A59D6Q46319113-AFCA4E56-7C7B-4761-852C-D6E60506D21DQ47760026-81386431-4ED7-44BF-8364-EBC8300D96F7Q47768978-55DDBC26-399F-4D52-ACED-C15224F5A4D1Q57106044-502C045A-F81B-445D-84A5-470F25D57311
P2860
Liposomal anthracyclines in metastatic breast cancer: clinical update.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Liposomal anthracyclines in metastatic breast cancer: clinical update.
@ast
Liposomal anthracyclines in metastatic breast cancer: clinical update.
@en
type
label
Liposomal anthracyclines in metastatic breast cancer: clinical update.
@ast
Liposomal anthracyclines in metastatic breast cancer: clinical update.
@en
prefLabel
Liposomal anthracyclines in metastatic breast cancer: clinical update.
@ast
Liposomal anthracyclines in metastatic breast cancer: clinical update.
@en
P1433
P1476
Liposomal anthracyclines in metastatic breast cancer: clinical update.
@en
P2093
Edgardo Rivera
P356
10.1634/THEONCOLOGIST.8-SUPPL_2-3
P478
P577
2003-01-01T00:00:00Z